Symbolbild · KI-generiert
Canopy Growth Corporation
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, DeeLish, Claybourne, MTL Cannabis, Low Key by MTL and R'belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond. Canopy Growth is Canada's leading provider of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds unconsolidated, non-controlling interest in Canopy USA, LLC ('Canopy USA'), which provides exposure to the U.S. THC market. Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being.
Company description as published by the issuer via TMX Money.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Canopy Growth Corporation | WEED | TSX | 389 Mio. USD |
| C4 Therapeutics, Inc. | CCCC | NASDAQ | 385 Mio. USD |
| Evolus, Inc. | EOLS | NASDAQ | 385 Mio. USD |
| Autolus Therapeutics plc | AUTL | NASDAQ | 397 Mio. USD |
| Larimar Therapeutics, Inc. | LRMR | NASDAQ | 397 Mio. USD |
| Assembly Biosciences, Inc. | ASMB | NASDAQ | 399 Mio. USD |
| Sutro Biopharma, Inc. | STRO | NASDAQ | 401 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.